全文获取类型
收费全文 | 28139篇 |
免费 | 15648篇 |
国内免费 | 6篇 |
出版年
2024年 | 10篇 |
2023年 | 43篇 |
2022年 | 196篇 |
2021年 | 538篇 |
2020年 | 2304篇 |
2019年 | 3910篇 |
2018年 | 3983篇 |
2017年 | 4216篇 |
2016年 | 4238篇 |
2015年 | 4137篇 |
2014年 | 3821篇 |
2013年 | 4319篇 |
2012年 | 1968篇 |
2011年 | 1681篇 |
2010年 | 3137篇 |
2009年 | 1865篇 |
2008年 | 746篇 |
2007年 | 369篇 |
2006年 | 342篇 |
2005年 | 360篇 |
2004年 | 318篇 |
2003年 | 305篇 |
2002年 | 286篇 |
2001年 | 255篇 |
2000年 | 188篇 |
1999年 | 136篇 |
1998年 | 13篇 |
1997年 | 16篇 |
1996年 | 8篇 |
1995年 | 14篇 |
1994年 | 11篇 |
1993年 | 7篇 |
1992年 | 9篇 |
1991年 | 5篇 |
1989年 | 3篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 5篇 |
1984年 | 2篇 |
1979年 | 2篇 |
1977年 | 2篇 |
1975年 | 4篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
1966年 | 2篇 |
1889年 | 1篇 |
1882年 | 1篇 |
1881年 | 1篇 |
1873年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
921.
922.
923.
Ole J Hamming Ewa Terczyńska‐Dyla Gabrielle Vieyres Ronald Dijkman Sanne E Jørgensen Hashaam Akhtar Piotr Siupka Thomas Pietschmann Volker Thiel Rune Hartmann 《The EMBO journal》2013,32(23):3055-3065
The IFNL4 gene is a recently discovered type III interferon, which in a significant fraction of the human population harbours a frameshift mutation abolishing the IFNλ4 ORF. The expression of IFNλ4 is correlated with both poor spontaneous clearance of hepatitis C virus (HCV) and poor response to treatment with type I interferon. Here, we show that the IFNL4 gene encodes an active type III interferon, named IFNλ4, which signals through the IFNλR1 and IL‐10R2 receptor chains. Recombinant IFNλ4 is antiviral against both HCV and coronaviruses at levels comparable to IFNλ3. However, the secretion of IFNλ4 is impaired compared to that of IFNλ3, and this impairment is not due to a weak signal peptide, which was previously believed. We found that IFNλ4 gets N‐linked glycosylated and that this glycosylation is required for secretion. Nevertheless, this glycosylation is not required for activity. Together, these findings result in the paradox that IFNλ4 is strongly antiviral but a disadvantage during HCV infection. 相似文献
924.
925.
Maud Martin Ilse Geudens Jonathan Bruyr Michael Potente Anouk Bleuart Marielle Lebrun Nicolas Simonis Christophe Deroanne Jean‐Claude Twizere Philippe Soubeyran Paul Peixoto Denis Mottet Veerle Janssens Wolf‐Karsten Hofmann Filip Claes Peter Carmeliet Richard Kettmann Holger Gerhardt Franck Dequiedt 《The EMBO journal》2013,32(18):2491-2503
926.
Taner Cavlar Tobias Deimling Andrea Ablasser Karl‐Peter Hopfner Veit Hornung 《The EMBO journal》2013,32(10):1440-1450
Extensive research on antiviral small molecules starting in the early 1970s has led to the identification of 10‐carboxymethyl‐9‐acridanone (CMA) as a potent type I interferon (IFN) inducer. Up to date, the mode of action of this antiviral molecule has remained elusive. Here we demonstrate that CMA mediates a cell‐intrinsic type I IFN response, depending on the ER‐resident protein STING. CMA directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route. Interestingly, while CMA displays extraordinary activity in phosphorylating IRF3 in the murine system, CMA fails to activate human cells that are otherwise responsive to STING ligands. This failure to activate human STING can be ascribed to its inability to bind to the C‐terminal ligand‐binding domain of human STING. Crystallographic studies show that two CMA molecules bind to the central Cyclic diguanylate ( c‐diGMP)‐binding pocket of the STING dimer and fold the lid region in a fashion similar, but partially distinct, to c‐diGMP. Altogether, these results provide novel insight into ligand‐sensing properties of STING and, furthermore, unravel unexpected species‐specific differences of this innate sensor. 相似文献
927.
928.
929.
Yun Kong Malene B Vester‐Christensen Katrine T‐B G Schjoldager Kirstine Lavrsen Sally Dabelsteen Nis B Pedersen Lara Marcos‐Silva Ramneek Gupta Eric Paul Bennett Ulla Mandel Søren Brunak Hans H Wandall Steven B Levery Henrik Clausen 《The EMBO journal》2013,32(10):1478-1488
Glycosylation is the most abundant and diverse posttranslational modification of proteins. While several types of glycosylation can be predicted by the protein sequence context, and substantial knowledge of these glycoproteomes is available, our knowledge of the GalNAc‐type O‐glycosylation is highly limited. This type of glycosylation is unique in being regulated by 20 polypeptide GalNAc‐transferases attaching the initiating GalNAc monosaccharides to Ser and Thr (and likely some Tyr) residues. We have developed a genetic engineering approach using human cell lines to simplify O‐glycosylation (SimpleCells) that enables proteome‐wide discovery of O‐glycan sites using ‘bottom‐up’ ETD‐based mass spectrometric analysis. We implemented this on 12 human cell lines from different organs, and present a first map of the human O‐glycoproteome with almost 3000 glycosites in over 600 O‐glycoproteins as well as an improved NetOGlyc4.0 model for prediction of O‐glycosylation. The finding of unique subsets of O‐glycoproteins in each cell line provides evidence that the O‐glycoproteome is differentially regulated and dynamic. The greatly expanded view of the O‐glycoproteome should facilitate the exploration of how site‐specific O‐glycosylation regulates protein function. 相似文献
930.
Yung‐Lin Hsieh Hong‐Yi Kuo Che‐Chang Chang Mandar T Naik Pei‐Hsin Liao Chun‐Chen Ho Tien‐Chi Huang Jen‐Chong Jeng Pang‐Hung Hsu Ming‐Daw Tsai Tai‐Huang Huang Hsiu‐Ming Shih 《The EMBO journal》2013,32(6):791-804
While numerous small ubiquitin‐like modifier (SUMO) conjugated substrates have been identified, very little is known about the cellular signalling mechanisms that differentially regulate substrate sumoylation. Here, we show that acetylation of SUMO E2 conjugase Ubc9 selectively downregulates the sumoylation of substrates with negatively charged amino acid‐dependent sumoylation motif (NDSM) consisting of clustered acidic residues located downstream from the core ψ‐K‐X‐E/D consensus motif, such as CBP and Elk‐1, but not substrates with core ψ‐K‐X‐E/D motif alone or SUMO‐interacting motif. Ubc9 is acetylated at residue K65 and K65 acetylation attenuates Ubc9 binding to NDSM substrates, causing a reduction in NDSM substrate sumoylation. Furthermore, Ubc9 K65 acetylation can be downregulated by hypoxia via SIRT1, and is correlated with hypoxia‐elicited modulation of sumoylation and target gene expression of CBP and Elk‐1 and cell survival. Our data suggest that Ubc9 acetylation/deacetylation serves as a dynamic switch for NDSM substrate sumoylation and we report a previously undescribed SIRT1/Ubc9 regulatory axis in the modulation of protein sumoylation and the hypoxia response. 相似文献